Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Carolyn Burns

Cardiovascular Disease Richmond, VA Medical Doctor

NPI 1063453801 CMS profile 3341

9000 Stony Point Pkwy, Richmond, VA 23235

Open in the dashboard

General payments

$40,958

186 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Carolyn Burns of Richmond, VA is reported in the CMS Open Payments database as having received $40,958 across 186 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $1,032 4
2022 General $3,003 4
2021 General $7,313 52
2020 General $9,388 36
2019 General $20,222 90

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Carolyn Burns
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Carolyn Burns were reported at $0. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Carolyn Burns Cardiovascular Disease median Middle half National median
2019 $20,222 $450 $127–$1,392 $163
2020 $9,388 $242 $77–$751 $114
2021 $7,313 $335 $101–$1,037 $132
2022 $3,003 $395 $121–$1,211 $149
2023 $1,032 $443 $136–$1,283 $160
2024 $0 $450 $136–$1,323 $164
2025 $0 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Amgen Inc. $38,399 64 payments
  2. Janssen Pharmaceuticals, Inc $389 19 payments
  3. Regeneron Healthcare Solutions, Inc. $364 12 payments
  4. Amarin Pharma Inc. $308 13 payments
  5. Pfizer Inc. $212 11 payments
  6. AstraZeneca Pharmaceuticals LP $205 11 payments
  7. Novartis Pharmaceuticals Corporation $140 7 payments
  8. Abbott Laboratories $98 5 payments
  9. Lundbeck LLC $98 5 payments
  10. Regeneron Pharmaceuticals, Inc. $95 1 payment
  11. Other $647 38 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $35,685 18 payments
  2. Food and Beverage $4,170 149 payments
  3. Travel and Lodging $1,030 15 payments
  4. Education $72 4 payments
Products named General payments · program years 2019–2023
  1. Repatha $38,399 64 payments
  2. XARELTO $389 19 payments
  3. PRALUENT $364 12 payments
  4. Vascepa $235 9 payments
  5. ELIQUIS $212 11 payments
  6. ENTRESTO $140 7 payments
  7. EVKEEZA $122 2 payments
  8. NORTHERA $98 5 payments
  9. NEXLETOL $89 5 payments
  10. JARDIANCE $79 4 payments
  11. Other $929 53 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

299

Median for Cardiology: 2,533

Drug cost

$110,894

Median for Cardiology: $485,213

Branded share of claims

62.2%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Repatha Sureclick Evolocumab Brand 163 $98,871
Praluent Pen Alirocumab Brand 23 $10,378
Ezetimibe Generic 46 $1,043
Rosuvastatin Calcium Generic 54 $477
Atorvastatin Calcium Generic 13 $126

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$11,099

Medicare's payments for the services billed

Medicare patients

94

Average age 72

Services billed

138

71 women, 23 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 65%
Arthritis 52%
Ischemic heart disease 34%
Osteoporosis 27%
Diabetes 22%
Atrial fibrillation 20%
Heart failure 19%
Depression 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

186 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record